Shifting to new targets in pharmacological prevention of cardiovascular diseases

Current Opinion in Lipidology

Volumn 20, Issue 5, 2009, Pages 361-362

  Nilsson, Jan ^b   Kovanen, Petri T ^a  

^a WIHURI RESEARCH INSTITUTE   (Finland)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR DISEASE; DRUG TARGETING; HUMAN; HYPERCHOLESTEROLEMIA; NONHUMAN; NOTE; PHARMACEUTICAL CARE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROPHYLAXIS; STATISTICAL SIGNIFICANCE;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; HUMANS;

EID: 73349129355     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32833158ce     Document Type: Note

References (13)

1. Petinen P, Lahti-Koski M, Vartiainen E, Puska P. Nutrition and cardiovascular disease in Finland since the early 19KKK70s: a success story. J Nutr Health Aging 2001; 5:150-154.
2. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006; 48:438-445.
3. Waters DD, Brotons C, Chiang CW, et al., Lipid Treatment Assessment Project 2 Investigators. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009; 120:28-34.
4. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol 2005; 46:1225-1228.
5. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352:1685-1695.
6. Pentikäinen MO, Öörni K, Ala-Korpela M, Kovanen PT. Modified LDL: trigger of atherosclerosis and inflammation in the arterial intima. J Intern Med 2000; 247:359-370. (Pubitemid 30180038)
7. Tabas I, Williams KJ, Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007; 116:1832-1844.
8. Tardif JC, McMurray JJ, Klug E, et al., Aggressive Reduction of Inflammation Stops Events (ARISE) Trial Investigators. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebocontrolled trial. Lancet 2008; 371:1761-1768.
9. Stocker R. Molecular mechanisms underlying the antiatherosclerotic and antidiabetic effects of probucol, succinobucol, and other probucol analogues. Curr Opin Lipidol 2009; 20:227-235.
10. Williams KJ, Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 1998; 9:471-474.
11. Rosenson RS, Hislop C, McConnell D, et al., PLASMA Investigators. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebocontrolled trial. Lancet 2009; 373:649-658.
12. Corson MA. Phospholipase A2 inhibitors in atherosclerosis: the race is on. Lancet 2009; 373:608-610.
13. Hansson GK, Nilsson J. Vaccination against atherosclerosis? Induction of atheroproteotive immunity. Semin lmmunopathol 2009; 31:95-101.